Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19791904 | 0.80 | — | — | |
| SCHEMBL14724919 | 0.80 | ALDH1A1 (0.39) | ALDH1A1TDP1TSHRSMN1; SMN2CYP3A4 | |
| SCHEMBL25967467 | 0.76 | OPRM1 (0.39) | ALDH1A1TDP1TSHRSMN1; SMN2CYP3A4 | |
| SCHEMBL4276990 | 0.75 | ALDH1A1 (0.39) | ALDH1A1TDP1TSHRSMN1; SMN2CYP3A4 | |
| SCHEMBL29227252 | 0.74 | OPRM1 (0.42) | ALDH1A1TDP1TSHRCYP3A4DNM1 | |
| SCHEMBL32675976 | 0.73 | ALDH1A1 (0.48) | ALDH1A1TDP1TSHRSMN1; SMN2CYP3A4 | |
| SCHEMBL4652951 | 0.73 | ALDH1A1 (0.48) | ALDH1A1TDP1TSHRSMN1; SMN2CYP3A4 | |
| SCHEMBL22756700 | 0.73 | OPRM1 (0.46) | TSHRDNM1OPRM1CA1 | |
| SCHEMBL12841152 | 0.73 | ALDH1A1 (0.37) | ALDH1A1TDP1TSHRSMN1; SMN2CYP3A4 | |
| SCHEMBL5181412 | 0.73 | ALDH1A1 (0.37) | ALDH1A1TDP1TSHRSMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020041301-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-02-27 | — | — | WO | disclosed |